Article info

Download PDFPDF
Cost-effectiveness analysis
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA
  1. Correspondence to Wendy A Davis
    University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia; wdavis{at}meddent.uwa.edu.au
View Full Text

Citation

Davis WA
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Publication history

  • First published May 1, 2010.
Online issue publication 
May 01, 2010

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.